Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
NKTR-214 plus Opdivo as first-line therapy had an overall response rate of 48 percent.
A new area of research is examining the use of checkpoint inhibitors before surgery, a practice known as neoadjuvant therapy.
Requires use of diagnostic tests for PD-L1 levels in tumor tissue from bladder cancer patients.
Decreased survival seen in some metastatic bladder cancer patients treated with pembrolizumab or atezolizumab monotherapy.
Researchers say adopting the treatment “could spare patients a lot of suffering from repeated surgeries and save health care costs.”
May is Bladder Cancer Awareness Month.
The link between the older interferon treatment and these cancers may be related to the drug’s low hep C cure rate.
Are immunotherapy and targeted therapies ready to replace toxic chemotherapy?
Certain types of bacteria were associated with greater disease progression while others were linked to improved survival.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.